The estimated Net Worth of Edward Andrle is at least $4.44 Миллион dollars as of 18 October 2019. Mr. Andrle owns over 29,718 units of LivaNova PLC stock worth over $3,060,620 and over the last 9 years he sold LIVN stock worth over $0. In addition, he makes $1,374,940 as Special Advisor at LivaNova PLC.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Andrle LIVN stock SEC Form 4 insiders trading
Edward has made over 5 trades of the LivaNova PLC stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 29,718 units of LIVN stock worth $2,062,132 on 18 October 2019.
The largest trade he's ever made was exercising 29,718 units of LivaNova PLC stock on 18 October 2019 worth over $2,062,132. On average, Edward trades about 3,278 units every 19 days since 2016. As of 18 October 2019 he still owns at least 64,502 units of LivaNova PLC stock.
You can see the complete history of Mr. Andrle stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Edward Andrle biography
Edward Andrle serves as Special Advisor of the Company. He was Strategy, Business Development And New Ventures/Emerging Therapies of the company. He is the current Vice President of Strategy and Business Development of Sorin, and joined the Sorin headquarters in Milan, Italy in September 2010. Ed, a US national, had a successful career in the medical device industry, initially with large US corporations like Baxter and Boston Scientific, before becoming an entrepreneur and a CEO of start-up companies like Teramed (endovascular stent-graft), Myocor (mitral valve surgery) and StarFire Medical (neurovascular technology). Ed has an MBA from the Stanford Graduate School of Business and a BS in Chemical Engineering from the University of Notre Dame.
What is the salary of Edward Andrle?
As the Special Advisor of LivaNova PLC, the total compensation of Edward Andrle at LivaNova PLC is $1,374,940. There are 3 executives at LivaNova PLC getting paid more, with Damien McDonald having the highest compensation of $7,131,930.
How old is Edward Andrle?
Edward Andrle is 62, he's been the Special Advisor of LivaNova PLC since 2020. There are 6 older and 14 younger executives at LivaNova PLC. The oldest executive at LivaNova PLC is Arthur Rosenthal, 73, who is the Independent Director.
What's Edward Andrle's mailing address?
Edward's mailing address filed with the SEC is 20 EASTBOURNE TERRANCE, , LONDON, X0, W2 6LG.
Insiders trading at LivaNova PLC
Over the last 9 years, insiders at LivaNova PLC have traded over $79,802,010 worth of LivaNova PLC stock and bought 4,000 units worth $268,530 . The most active insiders traders include William A Kozy, Two S.C.A.Tower 6 S. A R.L.... и Peter M Wilver. On average, LivaNova PLC executives and independent directors trade stock every 10 days with the average trade being worth of $315,922. The most recent stock trade was executed by Peter M Wilver on 15 June 2024, trading 2,680 units of LIVN stock currently worth $127,166.
What does LivaNova PLC do?
livanova plc is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. our advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems.at livanova, we understand the importance of bringing both clinical and economic value to our customers. we are a strong, market-leading medical technology and services company, offering a diverse product portfolio and global reach. livanova is listed on the nasdaq stock exchange under the ticker symbol “livn.” livanova has approximately 3,000 employees worldwide. we are headquartered in london (uk) and maintain a presence in more than 100 countries. livanova is a worldwide leader in advanced circulatory support, cardiopulmonary and neuromodulation, dedicated to creating meaningful products and therapies that transform lives each and every day.
What does LivaNova PLC's logo look like?
Complete history of Mr. Andrle stock trades at LivaNova PLC
LivaNova PLC executives and stock owners
LivaNova PLC executives and other stock owners filed with the SEC include:
-
Damien McDonald,
Chief Executive Officer, Director -
Keyna Skeffington,
Senior Vice President, General Counsel and Company Secretary -
Alistair Simpson,
Special Advisor -
Edward Andrle,
Special Advisor -
Damien McDonald,
CEO & Director -
Keyna Pidcock Skeffington,
Sr. VP, Gen. Counsel & Corp. Sec. -
Alex Shvartsburg,
CFO and Corp. VP of Financial Planning, Analysis & International Region -
Daniel Moore,
Independent Chairman of the Board -
Hugh Morrison,
Independent Director -
Alfred Novak,
Independent Director -
Francesco Bianchi,
Independent Director -
Arthur Rosenthal,
Independent Director -
Andrea Saia,
Independent Director -
Sharon O'Kane,
Independent Director -
William Kozy,
Independent Director -
Stacy Seng,
Independent Director -
Marco Dolci,
Head of Global Operations and R&D -
Roy Khoury,
President - International, Senior Vice President - Global Strategic Marketing -
Trui Hebbelinck,
Chief Human Resource Officer -
Alex Shvartsburg,
Interim Chief Financial Officer -
Stephanie Bolton,
Pres of International Region -
Paul R. Buckman,
Pres of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement -
Dr. Bryan D. Olin Ph.D.,
Sr. VP & Head of Product Devel. - Neuromodulation -
Trui Hebbelinck,
Chief HR Officer -
Matthew Joseph Dodds III,
Sr. VP of Corp. Devel. -
Deanna Wilke,
Director of Corp. Communications -
Lullo Stefano Di,
Pres Cardiac Rhythm Mgmt -
Michel Darnaud,
President Cardiac Surgery -
Thad Allen Huston,
Chief Financial Officer -
Vivid Sehgal,
CFO -
Two S.C.A.Tower 6 S. A R.L....,
-
Jacques Gutedel,
President Intercontinental -
Stefano Gianotti,
Director -
Piero Vecchi,
VP & Controller -
Pritpal Shinmar,
SR VP Global Market Access -
Robert Jason Richey,
President, Neuromodulation -
Douglas John Manko,
Chief Accounting Officer -
David S Wise,
SR VP HR & IT -
Todd C Schermerhorn,
Director -
Ahmet Tezel,
Chief Innovation Officer -
Brian Sheridan,
SR VP Genl Counsel & Secretary -
Andre Michel Ballester,
CEO -
Demetrio Mauro,
Chief Integration Officer -
James Christopher Barry,
Director -
Peter M Wilver,
Director -
Brooke Story,
Director -
Michael Damon Hutchinson,
Chief Legal Officer -
Stephanie Bolton,
President, Global Epilepsy -
Vladimir Makatsaria,
Chief Executive Officer